125 related articles for article (PubMed ID: 6893792)
1. Histologic classification as a prognostic criterion for canine lymphosarcoma.
Weller RE; Holmberg CA; Theilen GH; Madewell BR
Am J Vet Res; 1980 Aug; 41(8):1310-4. PubMed ID: 6893792
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of lymphocytic surface markers and histology in adult non-Hodgkin's lymphoma.
Bloomfield CD; Kersey JH; Brunning RD; Gajl-Peczalska KJ
Cancer Treat Rep; 1977 Sep; 61(6):963-70. PubMed ID: 332359
[TBL] [Abstract][Full Text] [Related]
3. Chemoimmunotherapy for canine lymphosarcoma.
Theilen GH; Worley M; Benjamini E
J Am Vet Med Assoc; 1977 Mar; 170(6):607-10. PubMed ID: 576595
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for canine lymphosarcoma.
Madewell BR
Am J Vet Res; 1975 Oct; 36(10):1525-8. PubMed ID: 1242622
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of some prognostic factors for advanced multicentric lymphosarcoma in the dog: 147 cases (1978-1981).
MacEwen EG; Hayes AA; Matus RE; Kurzman I
J Am Vet Med Assoc; 1987 Mar; 190(5):564-8. PubMed ID: 3558097
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic responses in dogs with lymphosarcoma and hypercalcemia.
Weller RE; Theilen GH; Madewell BR
J Am Vet Med Assoc; 1982 Nov; 181(9):891-3. PubMed ID: 6897239
[TBL] [Abstract][Full Text] [Related]
7. Levamisole as adjuvant to chemotherapy for canine lymphosarcoma.
MacEwen EG; Hayes AA; Mooney S; Patnaik A; Kurzman I; Hardy WD
J Biol Response Mod; 1985 Aug; 4(4):427-33. PubMed ID: 3839843
[TBL] [Abstract][Full Text] [Related]
8. Lymphocyte blastogenesis in dogs with lymphosarcoma.
Calvert CA; Dawe D; Leifer CE; Brown J
Am J Vet Res; 1982 Jan; 43(1):94-101. PubMed ID: 6896408
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy for canine lymphosarcoma: a prospective evaluation of specific and nonspecific immunomodulation.
Weller RE; Theilen GH; Madewell BR; Crow SE; Benjamini E; Villalobos A
Am J Vet Res; 1980 Apr; 41(4):516-21. PubMed ID: 6893260
[TBL] [Abstract][Full Text] [Related]
10. A retrospective analysis of the clinical results in relation to the Rappaport histological classification.
Brown TC; Peters MV; Bergsagel DE; Reid J
Br J Cancer Suppl; 1975 Mar; 2():174-86. PubMed ID: 1182069
[TBL] [Abstract][Full Text] [Related]
11. Carmustine, vincristine, and prednisone in the treatment of canine lymphosarcoma.
Ricci Lucas SR; Pereira Coelho BM; Marquezi ML; Franchini ML; Miyashiro SI; De Benedetto Pozzi DH
J Am Anim Hosp Assoc; 2004; 40(4):292-9. PubMed ID: 15238559
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prognostic factors for dogs with primary lung tumors: 67 cases (1985-1992).
McNiel EA; Ogilvie GK; Powers BE; Hutchison JM; Salman MD; Withrow SJ
J Am Vet Med Assoc; 1997 Dec; 211(11):1422-7. PubMed ID: 9394893
[TBL] [Abstract][Full Text] [Related]
13. Histologic classification as an indication of therapeutic response in malignant lymphoma of dogs.
Gray KN; Raulston GL; Gleiser CA; Jardine JH
J Am Vet Med Assoc; 1984 Apr; 184(7):814-7. PubMed ID: 6725115
[TBL] [Abstract][Full Text] [Related]
14. Histologic classification and immunophenotyping of canine non-Hodgkin's lymphomas: unexpected high frequency of T cell lymphomas with B cell morphology.
Teske E; Wisman P; Moore PF; van Heerde P
Exp Hematol; 1994 Nov; 22(12):1179-87. PubMed ID: 7925781
[TBL] [Abstract][Full Text] [Related]
15. Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival.
Ostrow SS; Diggs CH; Sutherland JC; Gustafson J; Wiernik PH
Cancer Treat Rep; 1981; 65(11-12):929-33. PubMed ID: 7028254
[TBL] [Abstract][Full Text] [Related]
16. Assessment of potential doubling time (Tpot), argyrophilic nucleolar organizer regions (AgNOR), and proliferating cell nuclear antigen (PCNA) as predictors of therapy response in canine non-Hodgkin's lymphoma.
Vail DM; Kisseberth WC; Obradovich JE; Moore FM; London CA; MacEwen EG; Ritter MA
Exp Hematol; 1996 Jun; 24(7):807-15. PubMed ID: 8647231
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, double-blind clinical trial using a canine model.
Vail DM; Chun R; Thamm DH; Garrett LD; Cooley AJ; Obradovich JE
Clin Cancer Res; 1998 Jun; 4(6):1567-71. PubMed ID: 9626479
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.
Valerius KD; Ogilvie GK; Fettman MJ; Walton JA; Richardson K; Powers BE; McNiel EA; Rogers QR
J Am Vet Med Assoc; 1999 Feb; 214(3):353-6. PubMed ID: 10023395
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
20. [Morphological analysis of spontaneous hemoblastoses in dogs and cats].
Khrustalev SA; Ponomar'kov VI; Khar'kovskaia NA
Arkh Patol; 1979; 41(5):23-30. PubMed ID: 110293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
